ASPCF News and Press, Acerus Pharmaceuticals Corp From 03/15/22

TORONTO, March 15, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and twelve-month period ended December 31, 2021. Unless otherwise noted, all amo...

TORONTO, March 10, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its fourth quarter and full year 2021 financial and operating results on Tuesday, March 15, 2022 before the market opens. The company will also host a conference call on Tuesd...

TORONTO, March 07, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced the closing of its previously-announced acquisition of Serenity Pharmaceuticals LLC (“Serenity...

Acerus Pharmaceuticals (OTCQB:ASPCF) is acquiring Miami-based Serenity LLC and the global rights to its Noctiva brand in a cash and stock deal. Noctiva is used for treating nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void. Within 90 days of the...

Creating a Leading Urology & Men’s Health Pharmaceutical Company Acerus to have access to two significant and growing addressable markets that represent more than 40 million people in the United States alone On a combined pro- forma basis, Acerus is projecte...

TORONTO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“ First Genera...

Verity Pharmaceuticals will begin promoting NATESTO to health care professionals throughout Puerto Rico in Q1, 2022. This agreement represents a new partnership and the continued expansion of NATESTO into new markets. TORONTO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceutica...

TORONTO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“ First Genera...

Acerus Pharmaceuticals Corporation (ASPCF) Q3 2021 Earnings Conference Call November 9, 2021 10:00 a.m. ET Company Representatives Ed Gudaitis - President, Chief Executive Officer Bob Motz - Chief Financial Officer Conference Call Participants Presentation Operator Good morning ladies and gen...

TORONTO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its third quarter 2021 financial and operating results on Tuesday, November 9, 2021 before the market opens. The company will also host a conference call on Tuesday, November 9...